Intensity Therapeutics (INTS) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Voting matters and shareholder proposals
Election of one Class II director, Mark A. Goldberg, for a three-year term expiring in 2028.
Ratification of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of the nominated director and auditor ratification.
Audit committee and external auditor matters
EisnerAmper LLP proposed for ratification as the external auditor for the upcoming fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Intensity Therapeutics
- Directors re-elected, stock plan approved, and auditor ratified with no Q&A from shareholders.INTS
AGM 20243 Feb 2026 - Shelf registration enables up to $150M in offerings, supporting late-stage oncology trials.INTSRegistration Filing16 Dec 2025
- Registering 394,500 shares for resale; lead cancer drug advancing to Phase 3.INTSRegistration Filing16 Dec 2025
- Shareholders to vote on a reverse stock split and potential adjournment to maintain Nasdaq compliance.INTSProxy Filing2 Dec 2025
- Shareholders will vote virtually on director election and auditor ratification, with board approval recommended.INTSProxy Filing2 Dec 2025
- Annual meeting to vote on directors, ESPP, and auditor, with all proposals board-recommended.INTSProxy Filing2 Dec 2025
- Stockholders will vote virtually on a reverse stock split to address Nasdaq compliance.INTSProxy Filing2 Dec 2025
- Vote on director elections, stock plan, and auditor ratification at the July 17 virtual meeting.INTSProxy Filing2 Dec 2025
- Key votes include a reverse stock split and possible meeting adjournment, both board-recommended.INTSProxy Filing2 Dec 2025